Profile data is unavailable for this security.
About the company
Hikma Pharmaceuticals PLC is a pharmaceutical company. The Company’s principal activities are the development, manufacturing, marketing and selling of a range of generic, branded and in-licensed pharmaceuticals products in solid, semi-solid, liquid and injectable final dosage forms. The Company operates through three segments: Injectables, Generics and Branded. Injectables segment supply hospitals across its markets with generic injectables, supported by its manufacturing facilities in the United States, Europe and Middle East/North Africa (MENA). Generics segment supply oral and other non-injectable generic and specialty branded products in the United States retail market. Branded segment supply branded generics and in-licensed patented products in MENA. It also markets its products in Canada and, which includes approximately 25 sterile injectable products, three in-licensed ophthalmic products and a pipeline of seven additional products.
- Revenue in GBP (TTM)2.03bn
- Net income in GBP151.82m
- Incorporated2005
- Employees8.84k
- LocationHikma Pharmaceuticals PLC1 New Burlington PlaceLONDON W1S 2HRUnited KingdomGBR
- Phone+44 207 399 2760
- Fax+44 207 399 2761
- Websitehttps://www.hikma.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Genus plc | 662.40m | 34.40m | 1.87bn | 3.33k | 54.14 | 3.23 | 26.52 | 2.82 | 0.5242 | 0.5242 | 10.08 | 8.79 | 0.6899 | -- | 5.76 | 199,218.00 | 2.79 | 3.23 | 3.23 | 3.80 | -- | -- | 4.05 | 5.04 | 1.36 | 51.58 | 0.3106 | 67.18 | 3.33 | 5.27 | -13.53 | 4.51 | 28.18 | 6.28 |
| Indivior PLC | 728.42m | -42.80m | 1.87bn | 928.00 | -- | 45.56 | -- | 2.57 | -0.375 | -0.375 | 5.04 | 0.3018 | 0.501 | 1.52 | 4.27 | 784,934.40 | -2.94 | 4.76 | -5.96 | 9.11 | 82.37 | 84.35 | -5.88 | 9.42 | 1.12 | -39.10 | 0.8445 | 0.00 | 13.91 | -3.79 | -136.59 | -- | -32.56 | -- |
| Worldwide Healthcare Trust PLC | -59.72m | -84.06m | 1.93bn | 0.00 | -- | 0.8674 | -- | -- | -1.28 | -1.28 | -0.9149 | 35.51 | -0.0233 | -- | -- | -- | -3.28 | 7.07 | -3.57 | 7.52 | -- | 86.92 | -- | 84.78 | -- | -- | 0.00 | 10.32 | -125.52 | -- | -129.67 | -- | -- | 3.33 |
| Dechra Pharmaceuticals plc | 726.80m | 40.10m | 2.99bn | 2.04k | 73.15 | 3.55 | 22.79 | 4.11 | 0.359 | 0.359 | 6.52 | 7.39 | 0.4975 | 1.67 | 6.87 | 356,974.50 | 2.74 | 3.55 | 3.06 | 4.00 | 57.15 | 56.74 | 5.52 | 7.22 | 1.40 | 11.54 | 0.3779 | 96.35 | 12.14 | 13.67 | 4.86 | 17.39 | 48.50 | 15.93 |
| Hikma Pharmaceuticals Plc | 2.03bn | 151.82m | 3.68bn | 8.84k | 25.04 | 2.13 | 11.96 | 1.81 | 0.6673 | 0.6673 | 9.03 | 7.83 | 0.5693 | 1.70 | 3.36 | 230,065.50 | 4.32 | 9.13 | 5.68 | 12.54 | 50.26 | 50.86 | 7.59 | 15.51 | 1.14 | 6.70 | 0.3739 | 31.08 | -1.41 | 5.39 | -55.34 | -- | 8.30 | 1.43 |
| Croda International Plc | 2.09bn | 649.30m | 9.03bn | 5.83k | 13.92 | 3.74 | 11.67 | 4.32 | 4.65 | 4.65 | 14.96 | 17.30 | 0.6051 | 2.43 | 5.85 | 358,678.10 | 18.92 | 12.85 | 22.04 | 15.05 | 47.17 | 45.61 | 31.27 | 20.16 | 1.43 | 23.80 | 0.2021 | 48.63 | 10.57 | 8.76 | 102.40 | 23.14 | -0.8817 | 5.41 |
| Holder | Shares | % Held |
|---|---|---|
| Wellington Management Co. LLPas of 22 Feb 2023 | 11.17m | 5.07% |
| JPMorgan International Bank Ltd.as of 02 Feb 2023 | 10.75m | 4.88% |
| BlackRock Advisors (UK) Ltd.as of 22 Feb 2023 | 9.14m | 4.15% |
| Capital Research & Management Co. (World Investors)as of 02 Feb 2023 | 8.37m | 3.80% |
| The Vanguard Group, Inc.as of 02 Feb 2023 | 4.14m | 1.88% |
| Royal London Asset Management Ltd.as of 02 Feb 2023 | 3.59m | 1.63% |
| FIL Investment Advisors (UK) Ltd.as of 02 Feb 2023 | 3.23m | 1.47% |
| Capital Research & Management Co. (Global Investors)as of 02 Feb 2023 | 2.39m | 1.08% |
| Abrdn Alternative Investments Ltd.as of 02 Feb 2023 | 2.23m | 1.01% |
| Northern Trust Global Investments Ltd. (Securities Lending)as of 02 Feb 2023 | 2.02m | 0.92% |
